-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21

Benzinga·04/21/2026 15:45:01
Listen to the news
Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a Buy rating and announces Price Target of $21.